Relative kidney hyperfiltration in primary aldosteronism: A meta-analysis

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 2, 2011, Pages 113-122

  Kuo, Chin Chi ^a   Wu, Vin Cent ^a   Tsai, Ching Wei ^a   Wu, Kwan Dun ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Meta analysis; primary aldosteronism; relative kidney hyperfiltration

Indexed keywords

ARTICLE; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; KIDNEY INJURY; PRIMARY HYPERALDOSTERONISM;

ADULT; HEMOFILTRATION; HUMANS; HYPERALDOSTERONISM; KIDNEY; MIDDLE AGED; QUALITY ASSURANCE, HEALTH CARE; REGRESSION ANALYSIS;

EID: 79958068506     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320310391331     Document Type: Article

References (54)

1. Mancia G., De Backer G., Dominiczak A., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 ; 25: 1105-1187. (Pubitemid 46924065)
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 ; 289: 2560-2572. (Pubitemid 37430158)
3. Calhoun DA, Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008 ; 51: 1403-1419.
4. Rossi GP Cardiac consequences of aldosterone excess in human hypertension. Am J Hypertens 2006 ; 19: 10-12. (Pubitemid 43217026)
5. Rossi GP, Sacchetto A., Visentin P., et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996 ; 27: 1039-1045. (Pubitemid 26140658)
6. Matsumura K., Fujii K., Oniki H., Oka M. and Iida M. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006 ; 19: 13-18. (Pubitemid 43217027)
7. Muiesan ML, Salvetti M., Paini A., et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008 ; 52: 529-534.
8. Catena C., Colussi G., Lapenna R., et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007 ; 50: 911-918. (Pubitemid 350287534)
9. Rocha R. and Funder JW The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002 ; 970: 89-100. (Pubitemid 35286086)
10. Rossi GP, Bernini G., Desideri G., et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006 ; 48: 232-238. (Pubitemid 44309817)
11. Sechi LA, Novello M., Lapenna R., et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006 ; 295: 2638-2645. (Pubitemid 43882339)
12. Reincke M., Rump LC, Quinkler M., et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009 ; 94: 869-875.
13. Rossi GP, Sechi LA, Giacchetti G., Ronconi V., Strazzullo P. and Funder JW Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008 ; 19: 88-90. (Pubitemid 351442920)
14. Ribstein J., Du Cailar G., Fesler P. and Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 2005 ; 16: 1320-1325. (Pubitemid 41716516)
15. Moher D., Cook DJ, Eastwood S., Olkin I., Rennie D. and Stroup DF Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999 ; 354: 1896-1900.
16. Bero L. and Rennie D. The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA 1995 ; 274: 1935-1938. (Pubitemid 26003064)
17. Prie D. and Friedlander G. The clinical assessment of renal function. In: Alex M. D, Cameron JS, Grunfeld J-P, et al., (eds.). Oxford Textbook of Clinical Nephrology. 3rd ed. New York: Oxford University Press, 2005, p. 47-64.
18. Catena C., Colussi G., Nadalini E., et al. Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clin J Am Soc Nephrol 2007 ; 2: 722-731.
19. Wu VC, Yang SY, Lin JW, et al. [abstr.] 2009 February. At the 7th Asian-Pacific Congress of Hypertension, Kuala Lumpur, Malaysia.
20. Brochner-Mortensen J., Giese J. and Rossing N. Renal inulin clearance versus total plasma clearance of 51Cr-EDTA. Scand J Clin Lab Invest 1969 ; 23: 301-305.
21. Brown SC and O'Reilly PH Iohexol clearance for the determination of glomerular filtration rate in clinical practice: evidence for a new gold standard. J Urol 1991 ; 146: 675-679.
22. Garnett ES, Parsons V. and Veall N. Measurement of glomerular filtration rate in man using a 51Cr-edetic-acid complex. Lancet 1967 ; 1: 818-819.
23. Hagstam KE, Nordenfelt I., Svensson L. and Svensson SE Comparison of different methods for determination of glomerular filtration rate in renal disease. Scand J Clin Lab Invest 1974 ; 34: 31-36.
24. Perrone RD, Steinman TI, Beck GJ, et al. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis 1990 ; 16: 224-235. (Pubitemid 20342441)
25. Goates JJ, Morton KA, Whooten WW, et al. Comparison of methods for calculating glomerular filtration rate: technetium-99m-DTPA scintigraphic analysis, protein-free and whole-plasma clearance of technetium-99m-DTPA and iodine-125-iothalamate clearance. J Nucl Med 1990 ; 31: 424-429. (Pubitemid 20144708)
26. Oriuchi N., Inoue T., Hayashi I., et al. Evaluation of gamma camera-based measurement of individual kidney function using iodine-123 orthoiodohippurate. Eur J Nucl Med 1996 ; 23: 371-375. (Pubitemid 26118321)
27. Lundqvist S., Hietala SO, Groth S. and Sjodin JG Evaluation of single-sample clearance calculations in 902 patients. A comparison of multiple and single sample techniques. Acta Radiol 1997 ; 38: 68-72. (Pubitemid 127459519)
28. Tauxe WN Determination of glomerular filtration rate by single-plasma sampling technique following injection of radioiodinated diatrizoate. J Nucl Med 1986 ; 27: 45-50. (Pubitemid 17023168)
29. DerSimonian R. and Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 ; 7: 177-188. (Pubitemid 17189972)
30. Higgins JP and Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med 2002 ; 21: 1539-1558. (Pubitemid 34746062)
31. Laird NM and Ware JH Random-effects models for longitudinal data. Biometrics 1982 ; 38: 963-974.
32. Kimura G., Uzu T., Nakamura S., Inenaga T. and Fujii T. High sodium sensitivity and glomerular hypertension/hyperfiltration in primary aldosteronism. J Hyperten 1996 ; 14: 1463-1468. (Pubitemid 27007817)
33. Wu VC, Chueh SC, Chang HW, et al. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma. Am J Kidney Dis 2009 ; 54: 665-673.
34. Letavernier E., Peyrard S., Amar L., Zinzindohoue F., Fiquet B. and Plouin PF Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens 2008 ; 26: 1816-1823.
35. Sechi LA and Catena C. The dual role of the kidney in primary aldosteronism: key determinant in rescue from volume expansion and persistence of hypertension. Am J Kidney Dis 2009 ; 54: 594-597.
36. Dworkin LD, Hostetter TH, Rennke HG and Brenner BM Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension. J Clin Invest 1984 ; 73: 1448-1461.
37. Gaede P., Vedel P., Parving HH and Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999 ; 353: 617-622. (Pubitemid 29087981)
38. Jerums G., Premaratne E., Panagiotopoulos S., Clarke S., Power DA and MacIsaac RJ New and old markers of progression of diabetic nephropathy. Diabetes Res Clin Pract 2008 ; 82 (Suppl 1). S30-37.
39. Liu Y., Nakagawa Y., Wang Y., et al. Increased glucocorticoid receptor and 11{beta}-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice. Diabetes 2005 ; 54: 32-40. (Pubitemid 40105092)
40. Sechi LA, Di Fabio A., Bazzocchi M., Uzzau A. and Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab 2009 ; 94: 1191-1197.
41. Palatini P., Mormino P., Dorigatti F., et al. Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertension: the HARVEST. Kidney Int 2006 ; 70: 578-584. (Pubitemid 44141586)
42. Redon J. and Ruilope LM Microalbuminuria as an intermediate endpoint in essential hypertension: evidence is coming. J Hypertens 2004 ; 22: 1679-1681. (Pubitemid 39141958)
43. Pontremoli R., Leoncini G., Ravera M., et al. Microalbuminuria, cardiovascular, and renal risk in primary hypertension. J Am Soc Nephrol 2002 ; 13 (Suppl 3). S169-172.
44. de Jong PE and Brenner BM From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int 2004 ; 66: 2109-2118. (Pubitemid 41115274)
45. Rocha R., Martin-Berger CL, Yang P., Scherrer R., Delyani J. and McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002 ; 143: 4828-4836. (Pubitemid 35397623)
46. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA and Brenner BM Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. J Am Soc Nephrol 2001 ; 12: 1315-1325. (Pubitemid 32472647)
47. Kimura G., Saito F., Kojima S., et al. Renal function curve in patients with secondary forms of hypertension. Hypertension 1987 ; 10: 11-15. (Pubitemid 17104006)
48. Hollenberg NK Aldosterone in the development and progression of renal injury. Kidney Int 2004 ; 66: 1-9. (Pubitemid 38870076)
49. Bianchi S., Bigazzi R. and Campese VM Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005 ; 46: 45-51. (Pubitemid 40848432)
50. Bomback AS, Kshirsagar AV, Amamoo MA and Klemmer PJ Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008 ; 51: 199-211.
51. Ortola FV, Ballermann BJ, Anderson S., Mendez RE and Brenner BM Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. J Clin Invest 1987 ; 80: 670-674. (Pubitemid 18003936)
52. Guyton AC Dominant role of the kidneys and accessory role of whole-body autoregulation in the pathogenesis of hypertension. Am J Hypertens 1989 ; 2: 575-585. (Pubitemid 19184136)
53. Braam B., Mitchell KD, Koomans HA and Navar LG Relevance of the tubuloglomerular feedback mechanism in pathophysiology. J Am Soc Nephrol 1993 ; 4: 1257-1274.
54. Cupples WA and Braam B. Assessment of renal autoregulation. Am J Physiol 2007 ; 292: F1105-1123.